A NEW DRUG TO TREAT TRIPLE NEGATIVE BREAST CANCER

Project description

A novel anti-metastatic treatment against triple negative breast cancer

Triple negative breast cancer (TNBC) is an aggressive type of breast cancer with great metastatic propensity. TNBC lacks expression of oestrogen receptors, and as such, there are fewer targeted and efficient treatment options. The EU-funded CanceRusolution project has developed a cytostatic drug that targets the cytoskeleton of TNBC cells, halting their metastatic potential and hence their aggressiveness. Researchers plan to test the treatment in an animal model of TNBC and perform pharmacokinetics analysis. Upscaling treatment production to clinical grade will pave the way towards clinical testing of the treatment, with significant ramifications for the future management of TNBC.

Fields of science

• medical and health sciences › clinical medicine › oncology › breast cancer
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmacokinetics

Programme(s)

• HORIZON.3.2 - European innovation ecosystems Main Programme

Topic(s)

• HORIZON-EIE-2021-SCALEUP-01-03 - Women TechEU

Call for proposal

HORIZON-EIE-2021-SCALEUP-01

See other projects for this call

Funding Scheme

HORIZON-AG-LS - HORIZON Lump Sum Grant

Coordinator

SOMETHING IN HANDS - INVESTIGACAOCIENTIFICA, LDA

Net EU contribution

€ 75 000,00

Address

Edificio Tec Labs, Campus Da Fcul
1749-016 Lisboa
Portugal

Region

Continente › Área Metropolitana de Lisboa › Área Metropolitana de Lisboa

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

No data